
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group is a promising company with significant strengths, such as a strong recurring revenue stream and a global presence. However, investors should be aware of potential competition, pricing challenges, and market risks, as well as past FDA warnings. Despite these challenges, MiniMed's focus on innovation and their partnerships may lead to future growth.
Bears say
Minimed Group is facing significant challenges with its stock as the company operates in a highly competitive market, with many established players and new entrants vying for market share. The company's recent gross margin decline and projected near-term spend increase will put pressure on its financial performance. Additionally, the diabetes market is highly dependent on external factors, such as healthcare policies and regulations, which could pose a risk to the company's future growth. Furthermore, MiniMed's struggles with product development timelines could leave it at a disadvantage compared to its competitors.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares